Rheumatoid Arthritis accounted for a 20.8% share of the global clinical trials within the Immunology therapy area in 2021, registering a decrease of 1.9% when compared with the last ten-year average of 22.7% share, according to GlobalData .

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials for Rheumatoid Arthritis

Industry sponsored trials held a 56.4% share of all the clinical trials for Rheumatoid Arthritis indication in 2021, registering a decrease of 0.9% when compared with the ten-year average of 57.3%. Non-industry sponsored trials accounted for a 43.6% share in 2021, registering an increase of 0.9% over the ten-year average of 42.7%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Rheumatoid Arthritis trials

Asia-Pacific was the top region for industry sponsored Rheumatoid Arthritis trials, accounting for a 66.1% share in 2021, when compared with the five-year average of 61.2% and ten-year average of 51.8%.

Europe was at the second position with a 24.0% share in 2021, over the five-year average of 32.4% and ten-year average of 42.7%, followed by North America with a 14.0% share in 2021, as against five-year and ten-year averages of 23.7% and 30.5% respectively.

Middle East and Africa stood fourth with a 5.0% share in 2021, compared with the five-year average of 6.0% and ten-year average of 9.4%, followed by South and Central America with a 0.8% share in 2021, over five-year and ten-year averages of 7.3% and 12.4% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Rheumatoid Arthritis trials, accounting for a 45.5% share in 2021, as against the five-year average of 33.4% and ten-year average of 19.5%.

The US held a 14.0% share in 2021, over the five-year average of 21.4% and ten-year average of 26.8%, followed by Russia with a 9.9% share in 2021, compared with the five-year and ten-year averages of 10.5% and 14.6% respectively.

Australia held an 8.3% share in 2021, as against the five-year average of 7.4% and ten-year average of 8.3%.

India held a 5.8% share in 2021, over the five-year and ten-year averages of 7.8% and 7.9% respectively.

Top regions of non-industry sponsored Rheumatoid Arthritis trials

Asia-Pacific was the top region for non-industry sponsored Rheumatoid Arthritis trials, accounting for a 50.0% share in 2021 when compared with the five-year average of 55.9% and ten-year average of 53.6%.

Europe was at the second position with a 26.0% share in 2021, over the five-year and ten-year averages of 23.8% and 26.8% respectively, followed by Middle East and Africa with a 14.6% share in 2021, as against the five-year average of 12.3% and ten-year average of 10.3%.

North America stood at the fourth position with a 6.3% share in 2021, compared with the five-year average of 8.3% and ten-year average of 9.7%, followed by South and Central America with a 3.1% share in 2021, over the five-year and ten-year averages of 1.8% and 1.8% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Rheumatoid Arthritis trials, accounting for a 30.2% share in 2021, as against the five-year average of 18.9% and ten-year average of 14.4%.

Iran held an 11.5% share in 2021, over the five-year average of 7.2% and ten-year average of 6.8%, followed by India with an 8.3% share, compared with the five-year and ten-year averages of 14.8% and 10.6% respectively.

The Netherlands held a 6.3% share in 2021, as against the five-year average of 4.9% and ten-year average of 5.5%.

The UK held a 5.2% share in 2021, over the five-year average of 3.5% and ten-year average of 3.9%.

Phase I trials lead industry sponsored clinical trials for Rheumatoid Arthritis in 2021

Phase I trials held a 78.1% share of industry sponsored clinical trials for Rheumatoid Arthritis in 2021, over the five-year average of 54.7% and ten-year average of 46.4%.

Phase II trials held a 9.4% share in 2021, as against the five-year average of 15.0% and ten-year average of 17.3%. Phase III trials held a 7.0% share in 2021, compared with the five-year and ten-year averages of 15.8% and 17.9% respectively.

Phase IV trials held a 5.5% share in 2021, over the five-year average of 14.6% and ten-year average of 18.4%.

Phase IV trials lead non-industry sponsored clinical trials for Rheumatoid Arthritis in 2021

Phase IV trials held a 32.3% share of non-industry sponsored clinical trials for Rheumatoid Arthritis in 2021, over the five-year average of 35.9% and ten-year average of 37.7%.

Phase II trials held a 31.3% share in 2021, as against the five-year average of 44.2% and ten-year average of 44.6%. Phase III trials held an 18.2% share, compared with the five-year and ten-year averages of 13.0% and 12.4% respectively.

Phase I trials held a 18.2% share in 2021, over the five-year average of 6.9% and ten-year average of 5.3%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.